Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX1 | Q9Y5S8 | 10/20 | 0.53 |
| ▸ | MAPT | P10636 | 7/20 | 0.53 |
| ▸ | GAA | P10253 | 6/20 | 0.53 |
| ▸ | MEN1 | O00255 | 3/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.53 |
| ▸ | SNCA | P37840 | 3/20 | 0.53 |
| ▸ | BCHE | P06276 | 2/20 | 0.53 |
| ▸ | ACHE | P22303 | 2/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.53 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.53 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 1/20 | 0.53 |
| ▸ | CNR1 | P21554 | 1/20 | 0.53 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.53 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.53 |
| ▸ | HTR2C | P28335 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1596912 | 0.83 | NOX1 (0.53) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL6005181 | 0.83 | NOX1 (0.53) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL28616409 | 0.79 | NOX1 (0.44) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL10530491 | 0.77 | NOX1 (0.67) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL30274184 | 0.77 | NOX1 (0.67) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL31730318 | 0.76 | NOX1 (0.43) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL15909029 | 0.76 | NOX1 (0.46) | NOX1MAPTGAAMEN1KMT2A | |
| Water SCHEMBL3136465 | 0.75 | NOX1 (0.57) | NOX1MAPTGAAMEN1KMT2A | |
| Phenothiazine SCHEMBL17006488 | 0.74 | NOX1 (0.94) | NOX1MAPTGAAMEN1KMT2A | |
| SCHEMBL194062 | 0.74 | NOX1 (0.61) | NOX1MAPTGAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-105175355-B | A kind of preparation method of 2- cyano-phenothiazines | 宁波季诺化学品有限公司 | 2018-08-14 | — | — | CN | disclosed |
| EP-2749556-B1 | An improved process for the preparation of pure cyamemazine and salts thereof | MICRO LABS LTD (IN) | 2018-07-25 | — | — | EP | disclosed |
| CN-106946811-A | A kind of industrial production process of the cyano-phenothiazine of environment-friendly type 2 | 西安彩晶光电科技股份有限公司 | 2017-07-14 | — | — | CN | disclosed |
| CN-106946811-A | A kind of industrial production process of the cyano-phenothiazine of environment-friendly type 2 | 西安彩晶光电科技股份有限公司 | 2017-07-14 | — | — | CN | disclosed |
| CN-106946811-A | A kind of industrial production process of the cyano-phenothiazine of environment-friendly type 2 | 西安彩晶光电科技股份有限公司 | 2017-07-14 | — | — | CN | disclosed |
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | Prosetta Antiviral, Inc. | 2017-06-01 | — | — | US | disclosed |
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | Prosetta Antiviral, Inc. | 2017-06-01 | — | — | US | disclosed |
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | Prosetta Antiviral, Inc. | 2017-06-01 | — | — | US | disclosed |
| CN-102958525-B | Antiviral compounds | 普罗瑟塔抗病毒股份有限公司 | 2017-05-24 | — | — | CN | disclosed |
| US-9382221-B2 | Compounds, compositions, and methods for treating alzheimer's disease | PROSETTA ANTIVIRAL INC. (US) | 2016-07-05 | — | — | US | disclosed |
| US-8759336-B2 | Antiviral compounds | PROSETTA ANTIVIRAL INC. (US) | 2014-06-24 | — | — | US | disclosed |
| EP-2585073-A1 | ANTIVIRAL COMPOUNDS | Prostetta Antiviral Inc. (US) | 2013-05-01 | — | — | EP | disclosed |
| CN-102958525-A | Antiviral compounds | PROSTETTA ANTIVIRAL INC | 2013-03-06 | — | — | CN | disclosed |
| US-20120238543-A1 | Antiviral Compounds | Prosetta Antiviral, Inc. (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012125983-A1 | ANTIVIRAL TREATMENTS | PROSETTA ANTIVIRAL INC. (US) | 2012-09-20 | — | — | WO | disclosed |
| US-20120157435-A1 | Antiviral Compounds | PROSETTA ANTIVIRAL INC. (US) | 2012-06-21 | — | — | US | disclosed |
| WO-2011137447-A1 | ANTIVIRAL COMPOUNDS | PROSTETTA ANTIVIRAL INC. (US) | 2011-11-03 | — | — | WO | disclosed |
| CN-1255390-C | Preparation of 2-cyanophenthiazine | UNIV SHANXI (CN) | 2006-05-10 | — | — | CN | disclosed |
| CN-1583732-A | Preparation of 2-cyanophenthiazine | UNIV SHANXI (CN) | 2005-02-23 | — | — | CN | disclosed |
| US-5049669-A | Also diuretics | RHONE-POULENC SANTE (FR) | 1991-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170151253-A1 | Compounds, Compositions, and Methods for Treating Alzheimer's Disease | PSEN1, APP, PSEN2 | NOX1 1944/4885MAPT 11/4885GAA 345/4885 |
| US-20120238543-A1 | Antiviral Compounds | MAVS, EIF2AK2, IRF3 | NOX1 2332/4885MAPT 1842/4885GAA 1003/4885 |
| US-20120157435-A1 | Antiviral Compounds | MAVS, ZC3HAV1, EIF2AK2 | NOX1 2140/4885MAPT 693/4885GAA 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.